Dallas, Texas 08/30/2013 (Financialstrend) – Pfizer Inc. (NYSE:PFE) had announced on Thursday that the pneumonia case accrual had successfully been completed in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) of age 65 years and older. It is worth noting that CAPiTA had been the largest investigation of its kind designed to evaluate the efficiency of Prevenar 13 in preventing the infection of community acquired pneumonia which was caused by the 13 pneumococcal serotypes included in the vaccine. The investigational research was carried out as an event driven study in which it is essential that the pre specified number of community acquired vaccine type pneumococcal pneumonia cases had to occur among the participants of the study before the determination of test results are announced.
It is worth noting that Prevenar 13 had already been approved by the Food and Drug Administration of the US for use in adults of age 50 years and older under the accelerated approval program of FDA. In line with such approval, Pfizer Inc. (NYSE:PFE) had taken up the CAPiTA to determine the effectiveness of the drug in the prevention of pneumococcal pneumonia. This study involves approximately 85000 subjects of age 65 years and older and this is first of its kind to be conducted on such a large scale.
Shares of Pfizer Inc. (NYSE:PFE) had loss of 0.39% over the previous close to end up on Thursday at $28.10 per share. The intraday variations of the share prices were found to be in between the range of $28.07 to $28.48 per share. The stock had reported the least price for the past one year at $23.55 and highest price at $31.15 per share. The stock had made around 22.08 million trades on Thursday, whereas the mean trading volume for the past month had been at 26.55 million shares per day. The company has 6.62 billion shares outstanding and institutional ownership of 76%.